1231 UBE2N promotes melanoma growth by maintaining MEK and FRA1 signaling
Publication
, Journal Article
Dikshit, A; Jin, J; Degan, S; Huang, J; Foster, M; Moseley, A; Li, C; Zhang, J
Published in: Journal of Investigative Dermatology
May 2018
Duke Scholars
Published In
Journal of Investigative Dermatology
DOI
ISSN
0022-202X
Publication Date
May 2018
Volume
138
Issue
5
Start / End Page
S209 / S209
Publisher
Elsevier BV
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Dikshit, A., Jin, J., Degan, S., Huang, J., Foster, M., Moseley, A., … Zhang, J. (2018). 1231 UBE2N promotes melanoma growth by maintaining MEK and FRA1 signaling. Journal of Investigative Dermatology, 138(5), S209–S209. https://doi.org/10.1016/j.jid.2018.03.1246
Dikshit, A., J. Jin, S. Degan, J. Huang, M. Foster, A. Moseley, C. Li, and J. Zhang. “1231 UBE2N promotes melanoma growth by maintaining MEK and FRA1 signaling.” Journal of Investigative Dermatology 138, no. 5 (May 2018): S209–S209. https://doi.org/10.1016/j.jid.2018.03.1246.
Dikshit A, Jin J, Degan S, Huang J, Foster M, Moseley A, et al. 1231 UBE2N promotes melanoma growth by maintaining MEK and FRA1 signaling. Journal of Investigative Dermatology. 2018 May;138(5):S209–S209.
Dikshit, A., et al. “1231 UBE2N promotes melanoma growth by maintaining MEK and FRA1 signaling.” Journal of Investigative Dermatology, vol. 138, no. 5, Elsevier BV, May 2018, pp. S209–S209. Crossref, doi:10.1016/j.jid.2018.03.1246.
Dikshit A, Jin J, Degan S, Huang J, Foster M, Moseley A, Li C, Zhang J. 1231 UBE2N promotes melanoma growth by maintaining MEK and FRA1 signaling. Journal of Investigative Dermatology. Elsevier BV; 2018 May;138(5):S209–S209.
Published In
Journal of Investigative Dermatology
DOI
ISSN
0022-202X
Publication Date
May 2018
Volume
138
Issue
5
Start / End Page
S209 / S209
Publisher
Elsevier BV
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences